Literature DB >> 30220236

A standard model of Alzheimer's disease?

Lary C Walker1, David G Lynn2, Yury O Chernoff3,4.   

Abstract

The recent Research Framework proposed by the US National Institute on Aging and the Alzheimer's Association (NIA-AA) recommends that Alzheimer's disease be defined by its specific biology rather than by non-specific neurodegenerative and syndromal features. By affirming markers of abnormal Aβ and tau proteins as the essential pathobiological signature of Alzheimer's disease, the Framework tacitly reinforces the amyloid (Aβ) cascade as the leading theory of Alzheimer pathogenesis. In light of recent evidence that the cascade is driven by the misfolding and templated aggregation of Aβ and tau, we believe that an empirically grounded Standard Model of Alzheimer's pathogenesis is within reach. A Standard Model can clarify and consolidate existing information, contextualize risk factors and the complex disease phenotype, identify testable hypotheses for future research, and pave the most direct path to effective prevention and treatment.

Entities:  

Keywords:  Abeta; Alzheimer; aging; amyloid; dementia; neurodegeneration; prion; proteopathy; seeding; tau

Mesh:

Substances:

Year:  2018        PMID: 30220236      PMCID: PMC6277193          DOI: 10.1080/19336896.2018.1525256

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  32 in total

Review 1.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

Review 2.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases.

Authors:  Mathias Jucker; Lary C Walker
Journal:  Nature       Date:  2013-09-05       Impact factor: 49.962

3.  A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.

Authors:  Thorlakur Jonsson; Jasvinder K Atwal; Stacy Steinberg; Jon Snaedal; Palmi V Jonsson; Sigurbjorn Bjornsson; Hreinn Stefansson; Patrick Sulem; Daniel Gudbjartsson; Janice Maloney; Kwame Hoyte; Amy Gustafson; Yichin Liu; Yanmei Lu; Tushar Bhangale; Robert R Graham; Johanna Huttenlocher; Gyda Bjornsdottir; Ole A Andreassen; Erik G Jönsson; Aarno Palotie; Timothy W Behrens; Olafur T Magnusson; Augustine Kong; Unnur Thorsteinsdottir; Ryan J Watts; Kari Stefansson
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

Review 4.  Toxic oligomer species of amyloid-β in Alzheimer's disease, a timing issue.

Authors:  Sylvain E Lesne
Journal:  Swiss Med Wkly       Date:  2014-11-06       Impact factor: 2.193

Review 5.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

Authors:  Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 6.  The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease.

Authors:  Susan M Catalano; Elizabeth C Dodson; Darrell A Henze; Joseph G Joyce; Grant A Krafft; Gene G Kinney
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

Review 7.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Li Shen; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2013-08-07       Impact factor: 21.566

Review 8.  Biology and genetics of prions causing neurodegeneration.

Authors:  Stanley B Prusiner
Journal:  Annu Rev Genet       Date:  2013       Impact factor: 16.830

Review 9.  Models of β-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism.

Authors:  Ilie-Cosmin Stancu; Bruno Vasconcelos; Dick Terwel; Ilse Dewachter
Journal:  Mol Neurodegener       Date:  2014-11-18       Impact factor: 14.195

Review 10.  The amyloid hypothesis of Alzheimer's disease at 25 years.

Authors:  Dennis J Selkoe; John Hardy
Journal:  EMBO Mol Med       Date:  2016-06-01       Impact factor: 12.137

View more
  9 in total

Review 1.  Application of yeast to studying amyloid and prion diseases.

Authors:  Yury O Chernoff; Anastasia V Grizel; Aleksandr A Rubel; Andrew A Zelinsky; Pavithra Chandramowlishwaran; Tatiana A Chernova
Journal:  Adv Genet       Date:  2020-05-04       Impact factor: 1.944

2.  Aβ Plaques.

Authors:  Lary C Walker
Journal:  Free Neuropathol       Date:  2020-10-30

Review 3.  Graph Models of Pathology Spread in Alzheimer's Disease: An Alternative to Conventional Graph Theoretic Analysis.

Authors:  Ashish Raj
Journal:  Brain Connect       Date:  2021-05-25

Review 4.  Development of molecular tools for diagnosis of Alzheimer's disease that are based on detection of amyloidogenic proteins.

Authors:  Konstantin Y Kulichikhin; Sergei A Fedotov; Maria S Rubel; Natalia M Zalutskaya; Anastasia E Zobnina; Oksana A Malikova; Nikolay G Neznanov; Yury O Chernoff; Aleksandr A Rubel
Journal:  Prion       Date:  2021-12       Impact factor: 3.931

5.  Nonlocal models in the analysis of brain neurodegenerative protein dynamics with application to Alzheimer's disease.

Authors:  Swadesh Pal; Roderick Melnik
Journal:  Sci Rep       Date:  2022-05-05       Impact factor: 4.996

Review 6.  Yeast Models for Amyloids and Prions: Environmental Modulation and Drug Discovery.

Authors:  Tatiana A Chernova; Yury O Chernoff; Keith D Wilkinson
Journal:  Molecules       Date:  2019-09-18       Impact factor: 4.411

7.  Risk of Alzheimer's Disease in Cancer Patients: Analysis of Mortality Data from the US SEER Population-Based Registries.

Authors:  Roman Mezencev; Yury O Chernoff
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639

8.  Protein-protein interactions in neurodegenerative diseases: A conspiracy theory.

Authors:  Travis B Thompson; Pavanjit Chaggar; Ellen Kuhl; Alain Goriely
Journal:  PLoS Comput Biol       Date:  2020-10-13       Impact factor: 4.475

9.  Pre-clinical dose-ranging efficacy, pharmacokinetics, tissue biodistribution, and toxicity of a targeted contrast agent for MRI of amyloid deposition in Alzheimer's disease.

Authors:  Andrew A Badachhape; Peter K Working; Mayank Srivastava; Prajwal Bhandari; Igor V Stupin; Laxman Devkota; Eric A Tanifum; Ananth V Annapragada; Ketan B Ghaghada
Journal:  Sci Rep       Date:  2020-09-30       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.